nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexrazoxane—TOP2A—Epirubicin—bone cancer	0.544	0.653	CbGbCtD
Dexrazoxane—TOP2A—Doxorubicin—bone cancer	0.289	0.347	CbGbCtD
Dexrazoxane—TOP2A—Gastric Cancer Network 1—C21orf33—bone cancer	0.00454	0.299	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—T—bone cancer	0.00263	0.173	CbGpPWpGaD
Dexrazoxane—Febrile neutropenia—Methotrexate—bone cancer	0.00129	0.00893	CcSEcCtD
Dexrazoxane—Blood lactate dehydrogenase increased—Epirubicin—bone cancer	0.00125	0.00865	CcSEcCtD
Dexrazoxane—Febrile neutropenia—Epirubicin—bone cancer	0.0012	0.00836	CcSEcCtD
Dexrazoxane—TOP2A—Daunorubicin—Epirubicin—bone cancer	0.0012	0.173	CbGdCrCtD
Dexrazoxane—TOP2A—Doxorubicin—Epirubicin—bone cancer	0.0012	0.173	CbGdCrCtD
Dexrazoxane—TOP2A—Idarubicin—Epirubicin—bone cancer	0.0012	0.173	CbGdCrCtD
Dexrazoxane—Phlebitis—Cisplatin—bone cancer	0.00119	0.00825	CcSEcCtD
Dexrazoxane—Blood lactate dehydrogenase increased—Doxorubicin—bone cancer	0.00115	0.00801	CcSEcCtD
Dexrazoxane—Cardiac failure congestive—Cisplatin—bone cancer	0.00113	0.00784	CcSEcCtD
Dexrazoxane—Febrile neutropenia—Doxorubicin—bone cancer	0.00111	0.00773	CcSEcCtD
Dexrazoxane—TOP2A—Idarubicin—Doxorubicin—bone cancer	0.00111	0.16	CbGdCrCtD
Dexrazoxane—TOP2A—Epirubicin—Doxorubicin—bone cancer	0.00111	0.16	CbGdCrCtD
Dexrazoxane—TOP2A—Daunorubicin—Doxorubicin—bone cancer	0.00111	0.16	CbGdCrCtD
Dexrazoxane—Hypercalcaemia—Epirubicin—bone cancer	0.00104	0.00724	CcSEcCtD
Dexrazoxane—Hyponatraemia—Cisplatin—bone cancer	0.00103	0.00714	CcSEcCtD
Dexrazoxane—Vaginal haemorrhage—Epirubicin—bone cancer	0.000979	0.00679	CcSEcCtD
Dexrazoxane—Hypercalcaemia—Doxorubicin—bone cancer	0.000965	0.0067	CcSEcCtD
Dexrazoxane—Blood creatinine increased—Cisplatin—bone cancer	0.000959	0.00666	CcSEcCtD
Dexrazoxane—Breast disorder—Cisplatin—bone cancer	0.000925	0.00642	CcSEcCtD
Dexrazoxane—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.000922	0.0064	CcSEcCtD
Dexrazoxane—Vaginal haemorrhage—Doxorubicin—bone cancer	0.000906	0.00629	CcSEcCtD
Dexrazoxane—Injection site pain—Epirubicin—bone cancer	0.000887	0.00616	CcSEcCtD
Dexrazoxane—Extravasation—Methotrexate—bone cancer	0.000887	0.00616	CcSEcCtD
Dexrazoxane—Neoplasm malignant—Epirubicin—bone cancer	0.000848	0.00589	CcSEcCtD
Dexrazoxane—Pancytopenia—Cisplatin—bone cancer	0.000841	0.00583	CcSEcCtD
Dexrazoxane—Extravasation—Epirubicin—bone cancer	0.00083	0.00576	CcSEcCtD
Dexrazoxane—Injection site pain—Doxorubicin—bone cancer	0.000821	0.0057	CcSEcCtD
Dexrazoxane—Neoplasm malignant—Doxorubicin—bone cancer	0.000785	0.00545	CcSEcCtD
Dexrazoxane—Stomatitis—Cisplatin—bone cancer	0.000769	0.00534	CcSEcCtD
Dexrazoxane—Extravasation—Doxorubicin—bone cancer	0.000768	0.00533	CcSEcCtD
Dexrazoxane—Blood bilirubin increased—Epirubicin—bone cancer	0.000766	0.00532	CcSEcCtD
Dexrazoxane—Creatinine increased—Epirubicin—bone cancer	0.000761	0.00528	CcSEcCtD
Dexrazoxane—Phosphatase alkaline increased—Epirubicin—bone cancer	0.000725	0.00503	CcSEcCtD
Dexrazoxane—Injection site reaction—Epirubicin—bone cancer	0.00072	0.005	CcSEcCtD
Dexrazoxane—Blood bilirubin increased—Doxorubicin—bone cancer	0.000709	0.00492	CcSEcCtD
Dexrazoxane—Creatinine increased—Doxorubicin—bone cancer	0.000704	0.00489	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Cisplatin—bone cancer	0.000696	0.00483	CcSEcCtD
Dexrazoxane—Sepsis—Methotrexate—bone cancer	0.000672	0.00466	CcSEcCtD
Dexrazoxane—Phosphatase alkaline increased—Doxorubicin—bone cancer	0.00067	0.00465	CcSEcCtD
Dexrazoxane—Injection site reaction—Doxorubicin—bone cancer	0.000666	0.00463	CcSEcCtD
Dexrazoxane—Oesophagitis—Epirubicin—bone cancer	0.000662	0.00459	CcSEcCtD
Dexrazoxane—Cardiac disorder—Cisplatin—bone cancer	0.000658	0.00456	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Cisplatin—bone cancer	0.000639	0.00443	CcSEcCtD
Dexrazoxane—Sepsis—Epirubicin—bone cancer	0.000629	0.00436	CcSEcCtD
Dexrazoxane—Alopecia—Cisplatin—bone cancer	0.000626	0.00435	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—TNFRSF11A—bone cancer	0.000622	0.041	CbGpPWpGaD
Dexrazoxane—Malnutrition—Cisplatin—bone cancer	0.000617	0.00428	CcSEcCtD
Dexrazoxane—Erythema—Cisplatin—bone cancer	0.000617	0.00428	CcSEcCtD
Dexrazoxane—Oesophagitis—Doxorubicin—bone cancer	0.000613	0.00425	CcSEcCtD
Dexrazoxane—Phlebitis—Epirubicin—bone cancer	0.00061	0.00424	CcSEcCtD
Dexrazoxane—Blood alkaline phosphatase increased—Epirubicin—bone cancer	0.000605	0.0042	CcSEcCtD
Dexrazoxane—Sepsis—Doxorubicin—bone cancer	0.000582	0.00404	CcSEcCtD
Dexrazoxane—Cardiac failure congestive—Epirubicin—bone cancer	0.00058	0.00403	CcSEcCtD
Dexrazoxane—Tremor—Cisplatin—bone cancer	0.000578	0.00401	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Cisplatin—bone cancer	0.000572	0.00397	CcSEcCtD
Dexrazoxane—Anaemia—Cisplatin—bone cancer	0.00057	0.00396	CcSEcCtD
Dexrazoxane—Phlebitis—Doxorubicin—bone cancer	0.000565	0.00392	CcSEcCtD
Dexrazoxane—Blood alkaline phosphatase increased—Doxorubicin—bone cancer	0.000559	0.00388	CcSEcCtD
Dexrazoxane—Malaise—Cisplatin—bone cancer	0.000556	0.00386	CcSEcCtD
Dexrazoxane—Leukopenia—Cisplatin—bone cancer	0.000552	0.00383	CcSEcCtD
Dexrazoxane—Cardiac failure congestive—Doxorubicin—bone cancer	0.000537	0.00372	CcSEcCtD
Dexrazoxane—Hyponatraemia—Epirubicin—bone cancer	0.000528	0.00366	CcSEcCtD
Dexrazoxane—Myalgia—Cisplatin—bone cancer	0.000525	0.00364	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000521	0.00362	CcSEcCtD
Dexrazoxane—Discomfort—Cisplatin—bone cancer	0.000519	0.0036	CcSEcCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—bone cancer	0.00051	0.0336	CbGpPWpGaD
Dexrazoxane—Breast disorder—Methotrexate—bone cancer	0.000508	0.00352	CcSEcCtD
Dexrazoxane—Infection—Cisplatin—bone cancer	0.0005	0.00347	CcSEcCtD
Dexrazoxane—Nervous system disorder—Cisplatin—bone cancer	0.000494	0.00343	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Cisplatin—bone cancer	0.000493	0.00342	CcSEcCtD
Dexrazoxane—Blood creatinine increased—Epirubicin—bone cancer	0.000493	0.00342	CcSEcCtD
Dexrazoxane—Skin disorder—Cisplatin—bone cancer	0.000489	0.00339	CcSEcCtD
Dexrazoxane—Hyponatraemia—Doxorubicin—bone cancer	0.000489	0.00339	CcSEcCtD
Dexrazoxane—Anorexia—Cisplatin—bone cancer	0.00048	0.00333	CcSEcCtD
Dexrazoxane—Breast disorder—Epirubicin—bone cancer	0.000475	0.0033	CcSEcCtD
Dexrazoxane—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000474	0.00329	CcSEcCtD
Dexrazoxane—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000464	0.00322	CcSEcCtD
Dexrazoxane—Pancytopenia—Methotrexate—bone cancer	0.000461	0.0032	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000459	0.00318	CcSEcCtD
Dexrazoxane—Blood creatinine increased—Doxorubicin—bone cancer	0.000456	0.00316	CcSEcCtD
Dexrazoxane—Dysphagia—Epirubicin—bone cancer	0.000455	0.00315	CcSEcCtD
Dexrazoxane—Neutropenia—Methotrexate—bone cancer	0.000454	0.00315	CcSEcCtD
Dexrazoxane—Dyspnoea—Cisplatin—bone cancer	0.000449	0.00311	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—DHFR—bone cancer	0.00044	0.029	CbGpPWpGaD
Dexrazoxane—Breast disorder—Doxorubicin—bone cancer	0.00044	0.00305	CcSEcCtD
Dexrazoxane—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000438	0.00304	CcSEcCtD
Dexrazoxane—Decreased appetite—Cisplatin—bone cancer	0.000438	0.00304	CcSEcCtD
Dexrazoxane—Pneumonia—Methotrexate—bone cancer	0.000436	0.00302	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Cisplatin—bone cancer	0.000435	0.00302	CcSEcCtD
Dexrazoxane—Infestation NOS—Methotrexate—bone cancer	0.000433	0.00301	CcSEcCtD
Dexrazoxane—Infestation—Methotrexate—bone cancer	0.000433	0.00301	CcSEcCtD
Dexrazoxane—Depression—Methotrexate—bone cancer	0.000432	0.003	CcSEcCtD
Dexrazoxane—Pancytopenia—Epirubicin—bone cancer	0.000432	0.003	CcSEcCtD
Dexrazoxane—Pain—Cisplatin—bone cancer	0.00043	0.00299	CcSEcCtD
Dexrazoxane—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000429	0.00298	CcSEcCtD
Dexrazoxane—Neutropenia—Epirubicin—bone cancer	0.000425	0.00295	CcSEcCtD
Dexrazoxane—Stomatitis—Methotrexate—bone cancer	0.000422	0.00293	CcSEcCtD
Dexrazoxane—Dysphagia—Doxorubicin—bone cancer	0.000421	0.00292	CcSEcCtD
Dexrazoxane—Feeling abnormal—Cisplatin—bone cancer	0.000415	0.00288	CcSEcCtD
Dexrazoxane—Weight decreased—Epirubicin—bone cancer	0.000411	0.00285	CcSEcCtD
Dexrazoxane—Pneumonia—Epirubicin—bone cancer	0.000408	0.00283	CcSEcCtD
Dexrazoxane—Infestation NOS—Epirubicin—bone cancer	0.000405	0.00281	CcSEcCtD
Dexrazoxane—Infestation—Epirubicin—bone cancer	0.000405	0.00281	CcSEcCtD
Dexrazoxane—Agranulocytosis—Methotrexate—bone cancer	0.000404	0.00281	CcSEcCtD
Dexrazoxane—Pancytopenia—Doxorubicin—bone cancer	0.000399	0.00277	CcSEcCtD
Dexrazoxane—Body temperature increased—Cisplatin—bone cancer	0.000398	0.00276	CcSEcCtD
Dexrazoxane—Stomatitis—Epirubicin—bone cancer	0.000395	0.00274	CcSEcCtD
Dexrazoxane—Neutropenia—Doxorubicin—bone cancer	0.000393	0.00273	CcSEcCtD
Dexrazoxane—Haemoglobin—Methotrexate—bone cancer	0.000391	0.00271	CcSEcCtD
Dexrazoxane—Haemorrhage—Methotrexate—bone cancer	0.000389	0.0027	CcSEcCtD
Dexrazoxane—Weight decreased—Doxorubicin—bone cancer	0.000381	0.00264	CcSEcCtD
Dexrazoxane—Agranulocytosis—Epirubicin—bone cancer	0.000378	0.00263	CcSEcCtD
Dexrazoxane—Pneumonia—Doxorubicin—bone cancer	0.000377	0.00262	CcSEcCtD
Dexrazoxane—Infestation—Doxorubicin—bone cancer	0.000375	0.0026	CcSEcCtD
Dexrazoxane—Infestation NOS—Doxorubicin—bone cancer	0.000375	0.0026	CcSEcCtD
Dexrazoxane—Haemoglobin—Epirubicin—bone cancer	0.000366	0.00254	CcSEcCtD
Dexrazoxane—Stomatitis—Doxorubicin—bone cancer	0.000366	0.00254	CcSEcCtD
Dexrazoxane—Haemorrhage—Epirubicin—bone cancer	0.000364	0.00253	CcSEcCtD
Dexrazoxane—Asthenia—Cisplatin—bone cancer	0.000361	0.00251	CcSEcCtD
Dexrazoxane—Cardiac disorder—Methotrexate—bone cancer	0.000361	0.0025	CcSEcCtD
Dexrazoxane—Oedema peripheral—Epirubicin—bone cancer	0.000358	0.00249	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Epirubicin—bone cancer	0.000358	0.00248	CcSEcCtD
Dexrazoxane—Angiopathy—Methotrexate—bone cancer	0.000353	0.00245	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Methotrexate—bone cancer	0.00035	0.00243	CcSEcCtD
Dexrazoxane—Agranulocytosis—Doxorubicin—bone cancer	0.00035	0.00243	CcSEcCtD
Dexrazoxane—Diarrhoea—Cisplatin—bone cancer	0.000344	0.00239	CcSEcCtD
Dexrazoxane—Alopecia—Methotrexate—bone cancer	0.000344	0.00238	CcSEcCtD
Dexrazoxane—Mental disorder—Methotrexate—bone cancer	0.000341	0.00236	CcSEcCtD
Dexrazoxane—Erythema—Methotrexate—bone cancer	0.000338	0.00235	CcSEcCtD
Dexrazoxane—Malnutrition—Methotrexate—bone cancer	0.000338	0.00235	CcSEcCtD
Dexrazoxane—Haemoglobin—Doxorubicin—bone cancer	0.000338	0.00235	CcSEcCtD
Dexrazoxane—Cardiac disorder—Epirubicin—bone cancer	0.000338	0.00234	CcSEcCtD
Dexrazoxane—Haemorrhage—Doxorubicin—bone cancer	0.000337	0.00234	CcSEcCtD
Dexrazoxane—Oedema peripheral—Doxorubicin—bone cancer	0.000332	0.0023	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Doxorubicin—bone cancer	0.000331	0.0023	CcSEcCtD
Dexrazoxane—Angiopathy—Epirubicin—bone cancer	0.00033	0.00229	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Epirubicin—bone cancer	0.000328	0.00228	CcSEcCtD
Dexrazoxane—Alopecia—Epirubicin—bone cancer	0.000322	0.00223	CcSEcCtD
Dexrazoxane—Vomiting—Cisplatin—bone cancer	0.00032	0.00222	CcSEcCtD
Dexrazoxane—Mental disorder—Epirubicin—bone cancer	0.000319	0.00221	CcSEcCtD
Dexrazoxane—Erythema—Epirubicin—bone cancer	0.000317	0.0022	CcSEcCtD
Dexrazoxane—Malnutrition—Epirubicin—bone cancer	0.000317	0.0022	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Methotrexate—bone cancer	0.000314	0.00218	CcSEcCtD
Dexrazoxane—Anaemia—Methotrexate—bone cancer	0.000313	0.00217	CcSEcCtD
Dexrazoxane—Cardiac disorder—Doxorubicin—bone cancer	0.000312	0.00217	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—DHFR—bone cancer	0.00031	0.0204	CbGpPWpGaD
Dexrazoxane—Angiopathy—Doxorubicin—bone cancer	0.000305	0.00212	CcSEcCtD
Dexrazoxane—Malaise—Methotrexate—bone cancer	0.000305	0.00212	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Doxorubicin—bone cancer	0.000303	0.00211	CcSEcCtD
Dexrazoxane—Leukopenia—Methotrexate—bone cancer	0.000303	0.0021	CcSEcCtD
Dexrazoxane—Nausea—Cisplatin—bone cancer	0.000299	0.00208	CcSEcCtD
Dexrazoxane—Alopecia—Doxorubicin—bone cancer	0.000297	0.00206	CcSEcCtD
Dexrazoxane—Cough—Methotrexate—bone cancer	0.000295	0.00205	CcSEcCtD
Dexrazoxane—Mental disorder—Doxorubicin—bone cancer	0.000295	0.00205	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Epirubicin—bone cancer	0.000294	0.00204	CcSEcCtD
Dexrazoxane—Malnutrition—Doxorubicin—bone cancer	0.000293	0.00203	CcSEcCtD
Dexrazoxane—Erythema—Doxorubicin—bone cancer	0.000293	0.00203	CcSEcCtD
Dexrazoxane—Anaemia—Epirubicin—bone cancer	0.000293	0.00203	CcSEcCtD
Dexrazoxane—Myalgia—Methotrexate—bone cancer	0.000288	0.002	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000286	0.00199	CcSEcCtD
Dexrazoxane—Malaise—Epirubicin—bone cancer	0.000286	0.00198	CcSEcCtD
Dexrazoxane—Discomfort—Methotrexate—bone cancer	0.000285	0.00198	CcSEcCtD
Dexrazoxane—Syncope—Epirubicin—bone cancer	0.000284	0.00197	CcSEcCtD
Dexrazoxane—Leukopenia—Epirubicin—bone cancer	0.000284	0.00197	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000282	0.0186	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—bone cancer	0.000281	0.0185	CbGpPWpGaD
Dexrazoxane—Loss of consciousness—Epirubicin—bone cancer	0.000278	0.00193	CcSEcCtD
Dexrazoxane—Cough—Epirubicin—bone cancer	0.000276	0.00192	CcSEcCtD
Dexrazoxane—Infection—Methotrexate—bone cancer	0.000274	0.0019	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Doxorubicin—bone cancer	0.000272	0.00189	CcSEcCtD
Dexrazoxane—Nervous system disorder—Methotrexate—bone cancer	0.000271	0.00188	CcSEcCtD
Dexrazoxane—Anaemia—Doxorubicin—bone cancer	0.000271	0.00188	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Methotrexate—bone cancer	0.00027	0.00188	CcSEcCtD
Dexrazoxane—Myalgia—Epirubicin—bone cancer	0.00027	0.00187	CcSEcCtD
Dexrazoxane—Skin disorder—Methotrexate—bone cancer	0.000268	0.00186	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000268	0.00186	CcSEcCtD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—EGFR—bone cancer	0.000268	0.0176	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—ZW10—bone cancer	0.000267	0.0176	CbGpPWpGaD
Dexrazoxane—Discomfort—Epirubicin—bone cancer	0.000266	0.00185	CcSEcCtD
Dexrazoxane—Malaise—Doxorubicin—bone cancer	0.000264	0.00183	CcSEcCtD
Dexrazoxane—Dry mouth—Epirubicin—bone cancer	0.000264	0.00183	CcSEcCtD
Dexrazoxane—Anorexia—Methotrexate—bone cancer	0.000263	0.00183	CcSEcCtD
Dexrazoxane—Syncope—Doxorubicin—bone cancer	0.000263	0.00182	CcSEcCtD
Dexrazoxane—Leukopenia—Doxorubicin—bone cancer	0.000262	0.00182	CcSEcCtD
Dexrazoxane—Loss of consciousness—Doxorubicin—bone cancer	0.000258	0.00179	CcSEcCtD
Dexrazoxane—Infection—Epirubicin—bone cancer	0.000257	0.00178	CcSEcCtD
Dexrazoxane—Cough—Doxorubicin—bone cancer	0.000256	0.00177	CcSEcCtD
Dexrazoxane—Shock—Epirubicin—bone cancer	0.000254	0.00177	CcSEcCtD
Dexrazoxane—Nervous system disorder—Epirubicin—bone cancer	0.000253	0.00176	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Epirubicin—bone cancer	0.000253	0.00176	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000252	0.00175	CcSEcCtD
Dexrazoxane—Skin disorder—Epirubicin—bone cancer	0.000251	0.00174	CcSEcCtD
Dexrazoxane—Insomnia—Methotrexate—bone cancer	0.00025	0.00173	CcSEcCtD
Dexrazoxane—Myalgia—Doxorubicin—bone cancer	0.000249	0.00173	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000248	0.00172	CcSEcCtD
Dexrazoxane—Discomfort—Doxorubicin—bone cancer	0.000247	0.00171	CcSEcCtD
Dexrazoxane—Anorexia—Epirubicin—bone cancer	0.000246	0.00171	CcSEcCtD
Dexrazoxane—Dyspnoea—Methotrexate—bone cancer	0.000246	0.00171	CcSEcCtD
Dexrazoxane—Somnolence—Methotrexate—bone cancer	0.000246	0.0017	CcSEcCtD
Dexrazoxane—Dry mouth—Doxorubicin—bone cancer	0.000244	0.00169	CcSEcCtD
Dexrazoxane—Decreased appetite—Methotrexate—bone cancer	0.00024	0.00167	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.00024	0.0158	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—ZW10—bone cancer	0.000239	0.0157	CbGpPWpGaD
Dexrazoxane—Gastrointestinal disorder—Methotrexate—bone cancer	0.000238	0.00166	CcSEcCtD
Dexrazoxane—Fatigue—Methotrexate—bone cancer	0.000238	0.00165	CcSEcCtD
Dexrazoxane—Infection—Doxorubicin—bone cancer	0.000238	0.00165	CcSEcCtD
Dexrazoxane—Pain—Methotrexate—bone cancer	0.000236	0.00164	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000236	0.00163	CcSEcCtD
Dexrazoxane—Shock—Doxorubicin—bone cancer	0.000235	0.00163	CcSEcCtD
Dexrazoxane—Nervous system disorder—Doxorubicin—bone cancer	0.000235	0.00163	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Doxorubicin—bone cancer	0.000234	0.00163	CcSEcCtD
Dexrazoxane—Insomnia—Epirubicin—bone cancer	0.000234	0.00162	CcSEcCtD
Dexrazoxane—Skin disorder—Doxorubicin—bone cancer	0.000232	0.00161	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	0.000231	0.0152	CbGpPWpGaD
Dexrazoxane—Dyspnoea—Epirubicin—bone cancer	0.00023	0.0016	CcSEcCtD
Dexrazoxane—Somnolence—Epirubicin—bone cancer	0.00023	0.00159	CcSEcCtD
Dexrazoxane—Anorexia—Doxorubicin—bone cancer	0.000228	0.00158	CcSEcCtD
Dexrazoxane—Feeling abnormal—Methotrexate—bone cancer	0.000228	0.00158	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Methotrexate—bone cancer	0.000226	0.00157	CcSEcCtD
Dexrazoxane—Decreased appetite—Epirubicin—bone cancer	0.000225	0.00156	CcSEcCtD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—TP53—bone cancer	0.000225	0.0148	CbGpPWpGaD
Dexrazoxane—Gastrointestinal disorder—Epirubicin—bone cancer	0.000223	0.00155	CcSEcCtD
Dexrazoxane—Fatigue—Epirubicin—bone cancer	0.000223	0.00155	CcSEcCtD
Dexrazoxane—Constipation—Epirubicin—bone cancer	0.000221	0.00153	CcSEcCtD
Dexrazoxane—Pain—Epirubicin—bone cancer	0.000221	0.00153	CcSEcCtD
Dexrazoxane—Urticaria—Methotrexate—bone cancer	0.000219	0.00152	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000218	0.0144	CbGpPWpGaD
Dexrazoxane—Abdominal pain—Methotrexate—bone cancer	0.000218	0.00152	CcSEcCtD
Dexrazoxane—Body temperature increased—Methotrexate—bone cancer	0.000218	0.00152	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000218	0.00151	CcSEcCtD
Dexrazoxane—Insomnia—Doxorubicin—bone cancer	0.000216	0.0015	CcSEcCtD
Dexrazoxane—Dyspnoea—Doxorubicin—bone cancer	0.000213	0.00148	CcSEcCtD
Dexrazoxane—Feeling abnormal—Epirubicin—bone cancer	0.000213	0.00148	CcSEcCtD
Dexrazoxane—Somnolence—Doxorubicin—bone cancer	0.000213	0.00148	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Epirubicin—bone cancer	0.000211	0.00147	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—GNA11—bone cancer	0.000211	0.0139	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—EZH2—bone cancer	0.00021	0.0138	CbGpPWpGaD
Dexrazoxane—Decreased appetite—Doxorubicin—bone cancer	0.000208	0.00144	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000206	0.00143	CcSEcCtD
Dexrazoxane—Fatigue—Doxorubicin—bone cancer	0.000206	0.00143	CcSEcCtD
Dexrazoxane—Urticaria—Epirubicin—bone cancer	0.000205	0.00143	CcSEcCtD
Dexrazoxane—Pain—Doxorubicin—bone cancer	0.000205	0.00142	CcSEcCtD
Dexrazoxane—Constipation—Doxorubicin—bone cancer	0.000205	0.00142	CcSEcCtD
Dexrazoxane—Abdominal pain—Epirubicin—bone cancer	0.000204	0.00142	CcSEcCtD
Dexrazoxane—Body temperature increased—Epirubicin—bone cancer	0.000204	0.00142	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—TUBB4B—bone cancer	0.000202	0.0133	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.000201	0.0133	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000199	0.0131	CbGpPWpGaD
Dexrazoxane—Asthenia—Methotrexate—bone cancer	0.000198	0.00138	CcSEcCtD
Dexrazoxane—Feeling abnormal—Doxorubicin—bone cancer	0.000197	0.00137	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000196	0.0129	CbGpPWpGaD
Dexrazoxane—Gastrointestinal pain—Doxorubicin—bone cancer	0.000196	0.00136	CcSEcCtD
Dexrazoxane—Pruritus—Methotrexate—bone cancer	0.000195	0.00136	CcSEcCtD
Dexrazoxane—Urticaria—Doxorubicin—bone cancer	0.00019	0.00132	CcSEcCtD
Dexrazoxane—Body temperature increased—Doxorubicin—bone cancer	0.000189	0.00131	CcSEcCtD
Dexrazoxane—Abdominal pain—Doxorubicin—bone cancer	0.000189	0.00131	CcSEcCtD
Dexrazoxane—Diarrhoea—Methotrexate—bone cancer	0.000189	0.00131	CcSEcCtD
Dexrazoxane—Asthenia—Epirubicin—bone cancer	0.000185	0.00129	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—RFC1—bone cancer	0.000183	0.0121	CbGpPWpGaD
Dexrazoxane—Pruritus—Epirubicin—bone cancer	0.000183	0.00127	CcSEcCtD
Dexrazoxane—Dizziness—Methotrexate—bone cancer	0.000183	0.00127	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—TUBB4B—bone cancer	0.000181	0.0119	CbGpPWpGaD
Dexrazoxane—Diarrhoea—Epirubicin—bone cancer	0.000177	0.00123	CcSEcCtD
Dexrazoxane—Vomiting—Methotrexate—bone cancer	0.000176	0.00122	CcSEcCtD
Dexrazoxane—Headache—Methotrexate—bone cancer	0.000173	0.0012	CcSEcCtD
Dexrazoxane—Asthenia—Doxorubicin—bone cancer	0.000172	0.00119	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.000171	0.0113	CbGpPWpGaD
Dexrazoxane—Dizziness—Epirubicin—bone cancer	0.000171	0.00119	CcSEcCtD
Dexrazoxane—Pruritus—Doxorubicin—bone cancer	0.000169	0.00117	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000166	0.011	CbGpPWpGaD
Dexrazoxane—Vomiting—Epirubicin—bone cancer	0.000164	0.00114	CcSEcCtD
Dexrazoxane—Nausea—Methotrexate—bone cancer	0.000164	0.00114	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—RFC1—bone cancer	0.000164	0.0108	CbGpPWpGaD
Dexrazoxane—Diarrhoea—Doxorubicin—bone cancer	0.000164	0.00114	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDK4—bone cancer	0.000163	0.0107	CbGpPWpGaD
Dexrazoxane—Headache—Epirubicin—bone cancer	0.000162	0.00112	CcSEcCtD
Dexrazoxane—Dizziness—Doxorubicin—bone cancer	0.000158	0.0011	CcSEcCtD
Dexrazoxane—Nausea—Epirubicin—bone cancer	0.000154	0.00107	CcSEcCtD
Dexrazoxane—Vomiting—Doxorubicin—bone cancer	0.000152	0.00106	CcSEcCtD
Dexrazoxane—Headache—Doxorubicin—bone cancer	0.00015	0.00104	CcSEcCtD
Dexrazoxane—Nausea—Doxorubicin—bone cancer	0.000142	0.000986	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—RB1—bone cancer	0.000142	0.00933	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000123	0.00813	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—CDK4—bone cancer	0.000118	0.0078	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—DHFR—bone cancer	0.000114	0.00749	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—DHFR—bone cancer	0.000102	0.0067	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—TP53—bone cancer	9.84e-05	0.00648	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	9.14e-05	0.00602	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	8.81e-05	0.00581	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CHEK2—bone cancer	8.49e-05	0.0056	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	7.95e-05	0.00524	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—JUN—bone cancer	7.63e-05	0.00503	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—BRCA2—bone cancer	7.2e-05	0.00474	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	6.25e-05	0.00412	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDK4—bone cancer	5.97e-05	0.00393	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDK4—bone cancer	5.34e-05	0.00352	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	5.24e-05	0.00346	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—RB1—bone cancer	5.19e-05	0.00342	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—TP53—bone cancer	5.04e-05	0.00332	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—RB1—bone cancer	4.64e-05	0.00306	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MDM2—bone cancer	3.96e-05	0.00261	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TP53—bone cancer	2.27e-05	0.0015	CbGpPWpGaD
